| Quality policy of the NAMMD | descarca documentul … |
MENUMENU
- AGENCY
- MEDICINES FOR HUMAN USE
- Important notifications – Medicines for human use
- Legislation – Medicines for human use
- Forms and tariffs – Medicines for human use
- Medicinal product authorisation
- Parallel import authorisation
- Health technologies assessment
- Clinical trials
- Last resort treatments
- Pharmacovigilance
- Report an adverse reaction
- Direct healthcare professionals communications
- Submit a medicinal product quality complaint
- Inform on medicinal product shortage
- Medicinal products under additional monitoring
- Pharmaceutical inspection
- Advertising
- Readability
- Standard terms
- Intra-Community deliveries notifications
- Drug discontinuity notifications
- Sponsorships – Medicines for human use
- Medicinal Product Index
- MEDICAL DEVICES
- Important notifications – Medical Devices
- Legislation – Medical Devices
- Forms and fees – Medical Devices
- European regulations on medical devices
- CE marking
- Definitions and classification of medical devices
- Registration of medical devices into the national database
- Grant of customs notice
- Grant of donation notice
- Grant of out-of-scope notice
- Vigilance
- Market surveillance
- In-use surveillance
- Clinical investigation
- Notified bodies
- Operation notice
- Record of EU/EEA service providers into the database
- Grant of notice for use
- Grant of periodic check bulletins
- Report an incident
- Sponsorships – Medical Devices
- Medical Devices Index
- INFORMATION FOR THE PUBLIC
- Management agenda
- Activity reports
- Requests for information
- Name of the person responsible for compliance with provisions of Law 544/2001
- Application form provided in Law 544/2001
- Challenge of decisions and associated forms for administrative complaint (refusal and failure to comply with legal deadlines)
- Public documents and NAMMDR managed/generated documents
- Implementation reports on Law 544/2001
- Budget – funding source
- Balance sheet
- Public procurement
- Declarations of interest
- Financial disclosure statements
- CONTACT
- RO